Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer

被引：4
|
作者：
Franco, Fernando [1 ]
Provencio, Mariano [1 ]
机构：
[1] Puerta Hierro Hosp, Med Oncol Dept, Manuel de Falla St 1, Madrid 28222, Spain
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷 / 10期
关键词：
OPEN-LABEL; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL;
D O I：
10.21037/jtd.2019.09.68
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4092 / 4095
页数：4
相关论文
共 50 条
  • [21] Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
    Huynh, Caroline
    Walsh, Logan A.
    Spicer, Jonathan D.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 563 - 580
  • [22] Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients
    Viteri, Santiago
    Rosell, Rafael
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S643 - S646
  • [23] Treatment of Non-Small Cell Lung Cancer Patients in the Intensive Care Units with EGFR-Tyrosine Kinase Inhibitors
    Lee, I.
    Yang, C.
    Shih, J.
    Yu, C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [24] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Kujtan, Lara
    Subramanian, Janakiraman
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (07) : 547 - 559
  • [25] Tyrosine-kinase inhibitors in the treatment of non-small cell lung cancer in usual clinical practice
    Caparros Romero, S.
    Ruiz Fuentes, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1553 - 1553
  • [26] Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer
    Barron, Feliciano
    Ramirez-Tirado, Laura-Alejandra
    Caballe-Perez, Enrique
    Sanchez, Gisela
    Cardona, Andres
    Arrieta, Oscar
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1269 - S1270
  • [27] Tyrosine-kinase inhibitors for non-small cell lung cancer - addition - EML
    [J]. SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 293 - 301
  • [28] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    [J]. ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [29] Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
    Rath, Barbara
    Plangger, Adelina
    Hamilton, Gerhard
    [J]. CANCER DRUG RESISTANCE, 2020, 3 (02) : 171 - 178
  • [30] The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer
    Tian, Y.
    Huang, J.
    Luo, Q.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S577 - S577
12345